Detalhe da pesquisa
1.
Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis.
Haematologica
; 107(3): 774-775, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35229573
2.
Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis.
Haematologica
; 106(4): 1182-1187, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32586908
3.
Matching-adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma.
Cancer Med
; 12(7): 8005-8017, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36726287
4.
The cost-effectiveness of pegaspargase versus native asparaginase for first-line treatment of acute lymphoblastic leukaemia: a UK-based cost-utility analysis.
Health Econ Rev
; 9(1): 40, 2019 Dec 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-31885053
5.
Effectiveness of Everolimus Versus Endocrine Monotherapy or Chemotherapy Among HR+/HER2- mBC Patients With Multiple Metastatic Sites.
Clin Ther
; 38(4): 905-17, 2016 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-26947172
6.
Physician experiences and preferences in the treatment of HR+/HER2- metastatic breast cancer in the United States: a physician survey.
Cancer Med
; 5(2): 209-20, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26686532
7.
Clinical outcomes among HR+/HER2- metastatic breast cancer patients with multiple metastatic sites: a chart review study in the US.
Exp Hematol Oncol
; 4: 31, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26693096
8.
Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2- Metastatic Breast Cancer.
Breast Cancer (Auckl)
; 9: 67-72, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26380551
9.
Real-world effectiveness of everolimus-based therapy versus endocrine monotherapy and chemotherapy in patients of HR+/HER2- breast cancer with liver metastasis in the USA.
Expert Opin Pharmacother
; 16(14): 2101-11, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26290278
10.
Everolimus-Based Therapy versus Chemotherapy among Patients with HR+/HER2- Metastatic Breast Cancer: Comparative Effectiveness from a Chart Review Study.
Int J Breast Cancer
; 2015: 240750, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26078883
11.
Real-world effectiveness of everolimus-based therapy versus fulvestrant monotherapy in HR(+)/HER2(-) metastatic breast cancer.
J Comp Eff Res
; 4(4): 315-26, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26274793
12.
Treatment patterns and duration in post-menopausal women with HR+/HER2- metastatic breast cancer in the US: a retrospective chart review in community oncology practices (2004-2010).
Curr Med Res Opin
; 31(2): 263-73, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25350226
13.
Everolimus use and associated factors among post-menopausal women with hormonal receptor positive/human epidermal growth factor receptor 2 negative metastatic breast cancer.
Curr Med Res Opin
; 31(8): 1573-82, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26074049
14.
Comparative effectiveness of everolimus-based therapy versus endocrine monotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: a retrospective chart review in community oncology practices in the US.
Curr Med Res Opin
; 31(6): 1095-103, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25971725
15.
Prognostic factors for survival following initiation of second-line treatment with everolimus for metastatic renal cell carcinoma: evidence from a nationwide sample of clinical practice in the United States.
Expert Opin Pharmacother
; 16(6): 805-19, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25766864
16.
Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices.
Curr Med Res Opin
; 30(10): 2041-50, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-24983741
17.
Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: synthesis of findings from two multi-practice chart reviews in the United States.
Curr Med Res Opin
; 30(11): 2343-53, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25105304